Compare QMCO & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMCO | INO |
|---|---|---|
| Founded | 1980 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.1M | 133.4M |
| IPO Year | 2025 | 1999 |
| Metric | QMCO | INO |
|---|---|---|
| Price | $23.03 | $1.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $10.50 | $6.75 |
| AVG Volume (30 Days) | 1.6M | ★ 4.7M |
| Earning Date | 02-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.34 | 54.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $372,827,000.00 | $42,220,086.00 |
| Revenue This Year | $0.32 | $20,156.19 |
| Revenue Next Year | $8.35 | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.65 | ★ 19.37 |
| 52 Week Low | $4.19 | $0.56 |
| 52 Week High | $27.80 | $2.72 |
| Indicator | QMCO | INO |
|---|---|---|
| Relative Strength Index (RSI) | 60.20 | 56.38 |
| Support Level | $5.22 | $1.22 |
| Resistance Level | $27.80 | $1.79 |
| Average True Range (ATR) | 1.77 | 0.10 |
| MACD | -0.29 | 0.00 |
| Stochastic Oscillator | 65.12 | 45.00 |
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.